Tsamba-stir-fried Tiebangchui: Attenuates the toxicity of raw Tiebangchui without compromising its analgesic efficacy in Caenorhabditis elegans through TRPV channel regulation.
Tsamba-stir-fried Tiebangchui may reduce the toxicity of raw Tiebangchui while maintaining its analgesic effects, according to findings in C. elegans.
Where it sits
this study against the rest of the vip (vasoactive intestinal polypeptide) corpusSummary and findings
This study explored the toxicity reduction and efficacy retention of tsamba-stir-fried Tiebangchui (TS-TBC) in Caenorhabditis elegans. The study identified changes in alkaloid content and proposed TRPV channel proteins as potential targets. The findings suggest that TS-TBC reduces the toxicity of raw TBC without compromising its analgesic efficacy.
Abstract
Ethnopharmacological relevance Tiebangchui (TBC) is a commonly used Tibetan medicine. However, its narrow therapeutic safety window necessitates strategies to reduce toxicity while preserving therapeutic efficacy. At present, tsamba-stir-fried TBC (TS-TBC) has become a characteristic pretreatment approach for TBC. Aim of the study This study aimed to preliminary explore the material basis and mechanism underlying toxicity reduction and efficacy retention in tsamba-stir-fried TBC. Materials and methods First, UV, UPLC-Q-Exactive-Orbitrap-MS and HPLC were employed to characterize chemical compounds of raw TBC and TS-TBC. Subsequently, we conducted comprehensive evaluation in analgesia efficacy, basic toxicity, overall toxicity, neurotoxicity and cardiotoxic-like toxicity of using C. elegans N2. Further, network pharmacology and molecular docking approaches were adopted to screen for the potential targets of TS-TBC. To clarify the molecular mechanism of TS-TBC, we performed assays using C. elegans N2 and five mutant strains, combined with qRT-PCR detection. Finally, a compounds-phenotype-gene network was constructed via correlation analysis. Results We preliminarily identified 77 alkaloids in raw TBC and 80 alkaloids in TS-TBC. The contents of aconitine, 3-deoxyaconitine and 3-acetylaconitine decreased after processing, while the level of benzoylaconine increased. TS-TBC treatment showed to reduce toxicity of raw TBC in C. elegans N2 without compromising its analgesic efficacy. According to the result of network pharmacology and molecular docking, TRPV channel proteins were identified as potential targets of TS-TBC. In C. elegans mutant strains, deficiency in ocr-1, ocr-2, ocr-3, ocr-4, or osm-9 genes led to the loss of TS-TBC efficacy. Similarly, deletion of ocr-2 or osm-9 genes enhanced TS-TBC-induced apoptosis, while ablation of ocr-4 or osm-9 abolished its antioxidant effect. qRT-PCR validation showed that TS-TBC could downregulate the expression of ocr-2, ocr-3, and ocr-4 genes, while it exerted no significant effect on osm-9 gene. Conclusions Our findings revealed that changes in the contents of characteristic alkaloids, rather than total alkaloids, constitute the material basis for the toxicity reduction and efficacy retention of TS-TBC, and TRPV channel proteins serve as its potential targets. These findings provide a scientific basis for the rational clinical application of processed TBC.
Background
This paper addresses the challenge of balancing the therapeutic efficacy and toxicity of Tiebangchui (TBC), a traditional Tibetan medicine. Previous studies have indicated that processing methods like tsamba-stir-frying may alter the safety profile of herbal medicines. Understanding the mechanisms behind these changes is crucial for optimizing clinical applications.
Methods
The study utilized UV, UPLC-Q-Exactive-Orbitrap-MS, and HPLC to characterize chemical compounds in raw and processed TBC. Analgesic efficacy, basic toxicity, overall toxicity, neurotoxicity, and cardiotoxic-like toxicity were evaluated using C. elegans N2. Network pharmacology and molecular docking were employed to identify potential targets, and qRT-PCR was used for gene expression analysis.
Results
The study identified 77 alkaloids in raw TBC and 80 alkaloids in TS-TBC. Notably, levels of aconitine, 3-deoxyaconitine, and 3-acetylaconitine decreased after processing, while benzoylaconine increased. TS-TBC treatment reduced toxicity without compromising analgesic efficacy. Gene deficiencies in ocr-1, ocr-2, ocr-3, ocr-4, or osm-9 resulted in loss of TS-TBC efficacy.
Interpretation
The findings suggest that specific changes in alkaloid content are responsible for the observed reduction in toxicity and retention of efficacy in TS-TBC. While the study provides interesting insights, the effect sizes and clinical relevance remain uncertain due to the use of C. elegans as a model organism. The study's limitations, including potential confounding factors and the need for human data, should be considered when interpreting the results.
Key findings
- 77 alkaloids identified in raw TBC and 80 alkaloids in TS-TBC.
- Levels of aconitine, 3-deoxyaconitine, and 3-acetylaconitine decreased after processing.
- TS-TBC treatment reduced toxicity of raw TBC in C. elegans N2 without compromising analgesic efficacy.
- Deficiency in ocr-1, ocr-2, ocr-3, ocr-4, or osm-9 genes led to loss of TS-TBC efficacy.
- TS-TBC downregulated the expression of ocr-2, ocr-3, and ocr-4 genes.
Limitations
- Based on C. elegans, which may not fully represent human physiology.
- No human data provided to confirm findings.
- Potential confounding factors not fully addressed.